|
|
|
Notice by the Ministry of Finance, the General Administration of Customs, the State Taxation Administration and the National Medical Products Administration of Issuing the List of the Second Group of Anti-cancer drugs and Rare Disease Drugs Subject to the Value-Added Tax Policies
[Effective]
|
|
财政部、海关总署、税务总局、药监局关于发布第二批适用增值税政策的抗癌药品和罕见病药品清单的公告
[现行有效]
|
|
【法宝引证码】
|
- Issuing authority：
Instrumentalities of the State Council,All Ministries,Ministry of Finance,All Agencies,General Administration of Customs,All Administrations,State Taxation Administration,Other Institutions,Others,All Administrations (others),State Drug Supervision & Administration Bureau (replaced)
- Document Number：
Announcement No. 39 [2020] of the Ministry of Finance, the General Administration of Customs, the State Taxation Administration and the National Medical Products Administration
-
Date issued：
09-30-2020
- Effective date：
10-01-2020
- Level of Authority：
Departmental Regulatory Documents
- Area of Law：Taxation
|
|
|
|
|
|
|
|
|
|
|
|
| Notice by the Ministry of Finance, the General Administration of Customs, the State Taxation Administration and the National Medical Products Administration of Issuing the List of the Second Group of Anti-cancer drugs and Rare Disease Drugs Subject to the Value-Added Tax Policies | | 财政部、海关总署、税务总局、药监局关于发布第二批适用增值税政策的抗癌药品和罕见病药品清单的公告 |
| (Announcement No. 39 [2020] of the Ministry of Finance, the General Administration of Customs, the State Taxation Administration and the National Medical Products Administration) | | （财政部、海关总署、税务总局、药监局公告2020年第39号） |
For the purpose of encouraging the development of the pharmaceutical industry and reducing the cost of medication for patients, beginning on October 1, 2020, as regards the anti-cancer drugs and rare disease drugs in Annex 1 of this Announcement, relevant value-added tax policies shall be implemented in accordance with the Notice of the Ministry of Finance, the General Administration of Customs, the State Taxation Administration and the National Medical Products Administration on the Value-Added Tax Policies for Anti-Cancer Drugs (No. 47 [2018], Ministry of Finance) and the Notice of the Ministry of Finance, the General Administration of Customs, the State Taxation Administration and the National Medical Products Administration on the VAT Policies on Drugs for Rare Diseases (No. 24 [2019], Ministry of Finance). The tariff lines of some anti-cancer drugs and rare-disease drugs previously issued in the aforesaid notices shall be determined according to Annex 2.
．．．．．． | | 为鼓励制药产业发展，降低患者用药成本，自2020年10月1日起，本公告附件1中的抗癌药品和罕见病药品，按照《财政部 海关总署 税务总局 国家药品监督管理局关于抗癌药品增值税政策的通知》（财税〔2018〕47号）、《财政部 海关总署 税务总局 药监局关于罕见病药品增值税政策的通知》（财税〔2019〕24号）规定执行相关增值税政策。上述通知已发布的部分抗癌药品和罕见病药品按附件2确定税号。
．．．．．． |
|
Dear visitor, as a premium member of this database, you will get complete access to all content.Please go premium and get more.
1. To become a premium member, please call 400-810-8266 Ext. 171.
2. Binding to the account with access to this database.
3. Apply for a trial account.
4. To get instant access to a document, you can Pay Amount 【￥300.00】 for your single purchase. | |
您好：您现在要进入的是北大法宝英文库会员专区。
如您是我们英文用户可直接 登录，进入会员专区查询您所需要的信息；如您还不是我们 的英文用户；您可通过网上支付进行单篇购买，支付成功后即可立即查看本篇内容。
Tel: +86 (10) 82689699, +86 (10) 82668266 ext. 153
Mobile: +86 13311570713
Fax: +86 (10) 82668268
E-mail:info@chinalawinfo.com
|
| | | | | | | | |
Scan QR Code and Read on Mobile
|
|
|
|
|
|
Message: Please kindly comment on the present translation.
|
|
|
|
|
|
|
|
|
Translations are by lawinfochina.com, and we retain exclusive copyright over content
found on our website except for content we publish as authorized by respective copyright
owners or content that is publicly available from government sources.
Due to differences in language, legal systems, and culture, English translations
of Chinese law are for reference purposes only. Please use the official Chinese-language
versions as the final authority. Lawinfochina.com and its staff will not be directly
or indirectly liable for use of materials found on this website.
We welcome your comments and suggestions, which assist us in continuing to improve
the quality of our materials as we dynamically expand content.
|
|
|
|
|
|